Blue Owl Capital Holdings LP Sells 695,000 Shares of Tango Therapeutics, Inc. $TNGX

Key Points

• Blue Owl Capital cut its stake in Tango Therapeutics by 85.3% in Q3, selling 695,000 shares and leaving it with 119,416 shares (about 0.09% of the company) valued at roughly $1.0M.
• Insiders sold 113,633 shares worth $1.42M over the last quarter — including Director Barbara Weber (30,519 shares) and CFO Daniella Beckman (10,317 shares) on Feb. 3 — and insiders now own 7.5% of the stock.
• TNGX opened at $16.95 (1‑year range $1.03–$17.63) with a market cap of ~$2.28B; quarterly EPS of -$0.29 slightly beat estimates, and analysts hold a consensus "Moderate Buy" with a $18.25 target after multiple price‑target raises.

Blue Owl Capital Holdings LP cut its stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 85.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 119,416 shares of the company's stock after selling 695,000 shares during the period. Blue Owl Capital Holdings LP owned about 0.09% of Tango Therapeutics worth $1,003,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Invesco Ltd. increased its position in Tango Therapeutics by 138.8% in the first quarter. Invesco Ltd. now owns 70,517 shares of the company's stock worth $97,000 after buying an additional 40,983 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Tango Therapeutics during the 1st quarter valued at about $195,000. Dynamic Technology Lab Private Ltd grew its stake in shares of Tango Therapeutics by 139.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company's stock valued at $35,000 after acquiring an additional 15,037 shares during the period. Woodline Partners LP increased its holdings in Tango Therapeutics by 28.3% in the 1st quarter. Woodline Partners LP now owns 506,188 shares of the company's stock worth $693,000 after acquiring an additional 111,791 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in Tango Therapeutics by 270.6% in the 1st quarter. Jane Street Group LLC now owns 352,897 shares of the company's stock worth $483,000 after acquiring an additional 257,668 shares in the last quarter. Institutional investors own 78.99% of the company's stock.

Insider Buying and Selling

In related news, Director Barbara Weber sold 30,519 shares of the firm's stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $374,162.94. Following the completion of the transaction, the director directly owned 1,629,254 shares of the company's stock, valued at approximately $19,974,654.04. This trade represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Daniella Beckman sold 10,317 shares of Tango Therapeutics stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $126,486.42. Following the completion of the sale, the chief financial officer owned 184,297 shares in the company, valued at approximately $2,259,481.22. This represents a 5.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 113,633 shares of company stock worth $1,420,857. 7.50% of the stock is owned by insiders.

Tango Therapeutics Price Performance

TNGX stock opened at $16.95 on Friday. Tango Therapeutics, Inc. has a 1-year low of $1.03 and a 1-year high of $17.63. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -19.48 and a beta of 1.76. The business has a 50 day simple moving average of $11.86 and a two-hundred day simple moving average of $9.44.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 66.01%. Sell-side analysts anticipate that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Key Stories Impacting Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Clinical collaboration with Erasca to test ERAS‑0015/vopimetostat in MTAP‑deleted, RAS‑mutant cancers expands Tango’s clinical footprint and creates near‑term partnership newsflow that likely drove buying interest and record highs. TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
• Positive Sentiment: HC Wainwright sharply raised its price target to $27 (buy), a large explicit upside that can boost sentiment and buy‑side conviction. HC Wainwright price target raise
• Positive Sentiment: Guggenheim raised its target to $20 and reiterated a buy rating, adding to analyst momentum and supporting the share‑price lift. Guggenheim price target raise
• Positive Sentiment: Wedbush raised its target to $19 with an “outperform” rating, another vote of confidence from sell‑side analysts that can attract new buyers. Wedbush price target raise
• Positive Sentiment: An investment firm added ~1.1M shares (~$9.5M), increasing its reported position materially — institutional buying that signals conviction and can underpin the rally. Investment Firm Bets Big on TNGX Stock
• Neutral Sentiment: Quarterly results beat EPS estimates by $0.02 (reported -$0.29 vs. -$0.31) — a modest positive but company remains unprofitable with negative margins and ROE, so financials are unlikely to change valuation narrative immediately. Tango Therapeutics press release
• Negative Sentiment: A Seeking Alpha piece warns against buying into the rally despite PRMT5 promise, highlighting clinical, competitive and valuation risks that could limit upside or prompt pullbacks if trial data or execution falter. Tango Therapeutics: I'm Not Buying Into Latest Rally

Analysts Set New Price Targets

TNGX has been the topic of several analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Tango Therapeutics in a report on Wednesday, January 21st. Wall Street Zen cut shares of Tango Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday. Piper Sandler raised their price objective on shares of Tango Therapeutics from $11.00 to $14.00 and gave the company an "overweight" rating in a research report on Friday, January 16th. Jefferies Financial Group restated a "buy" rating and set a $18.00 target price on shares of Tango Therapeutics in a research note on Thursday. Finally, Mizuho started coverage on shares of Tango Therapeutics in a report on Monday, February 23rd. They issued an "outperform" rating and a $19.00 target price for the company. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $18.25.

Tango Therapeutics Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.

Want to see what other hedge funds are holding TNGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.